GAITHERSBURG, Md., Sept. 7, 2011 (GLOBE NEWSWIRE) -- Cytomedix, Inc. (OTCBB:CMXI) (the "Company"), a leading developer of biologically active regenerative therapies for wound care, inflammation and angiogenesis, today announced that two poster presentations highlighting the clinical merits of the Company's AutoloGel™ System in wound management will be presented at the 26th Annual Clinical Symposium on Advances in Skin & Wound Care: The Conference for Prevention and Healing, to be held at the Gaylord National Hotel & Convention Center in National Harbor, Maryland from September 9 through 12, 2011.
The AutoloGel System, a device for the production of autologous platelet rich plasma ("PRP") gel, is the only PRP device cleared by the U.S. Food and Drug Administration for use in wound management.
The Advances in Skin & Wound Care Poster Session will take place Saturday, September 10th from 10:30 a.m. to 1:30 p.m. and from 5:00 p.m. to 7:00 p.m. in the Exhibit Hall. Poster presenters will be available during these times. The following posters highlighting Cytomedix's PRP technology will be presented.
-
Using Platelet Rich Plasma Gel (PRP Gel) for Rapid Size Reduction in Pressure Ulcers Presented by Carelyn P. Fylling, R.N., M.S.N., C.W.S, C.L.N.C., Vice President, Professional Services and Laurie M. Rappl, PT, DPT, CSW, Clinical Development Liaison at Cytomedix, Inc.
- Positive Wound Healing Progress Using Platelet Rich Plasma (PRP) Gel in Patients With Low Albumin and Hemoglobin Presented by Carelyn P. Fylling
"We are delighted to have these two compelling clinical studies presented at this year's conference before an audience of some 1,000 multidisciplinary practitioners, including nurses, physicians, podiatrists, physical therapists, dietitians and others who manage skin and wound care patients across the continuum of care. These data underscore the clinical utility of AutoloGel to rapidly and effectively improve healing in a variety of wound management indications," noted Martin P. Rosendale, Chief Executive Officer of Cytomedix. "The ongoing presentation and publication of positive clinical data forms the foundation of our sales and marketing strategy, and should provide the impetus to drive clinical adoption of the AutoloGel System as it significantly and reliably improves the rate of complete healing, speed and progress to healing, and quality of life for patients suffering with these non-healing wounds."
About Cytomedix, Inc.
Cytomedix develops, sells and licenses regenerative biological therapies primarily for wound care, inflammation and angiogenesis. The Company markets the AutoloGel™ System, a device for the production of platelet rich plasma ("PRP") gel derived from the patient's own blood for use on a variety of exuding wounds; the Angel® Whole Blood Separation System, a blood processing device and disposable products used for the separation of whole blood into red cells, platelet poor plasma ("PPP") and PRP in surgical settings; and the activAT® Autologous Thrombin Processing Kit, which produces autologous thrombin serum from PPP. The activAT® kit is sold exclusively in Europe and Canada, where it provides a completely autologous, safe alternative to bovine-derived products. The Company is pursuing a multi-faceted strategy to penetrate the chronic wound market with its products, as well as opportunities for the application of AutoloGel™ and PRP technology into other markets such as hair transplantation and orthopedics while actively seeking complementary products for the wound care market. Additional information regarding Cytomedix is available at www.cytomedix.com.
Safe Harbor Statement
Statements contained in this communication not relating to historical facts are forward-looking statements that are intended to fall within the safe harbor rule for such statements under the Private Securities Litigation Reform Act of 1995. The information contained in the forward-looking statements is inherently uncertain, and Cytomedix's actual results may differ materially due to a number of factors, many of which are beyond Cytomedix's ability to predict or control, including among others, the likelihood of obtaining a positive reimbursement determination by the CMS following the Company's submission, the likelihood and the extent of beneficial effect of such determination on CMS costs and care, viability and effectiveness of the Company's sales approach and overall marketing strategies, the outcome of development or regulatory review of CT-112, commercial success or acceptance by the medical community, competitive responses, the Company's ability to raise additional capital and to continue as a going concern, and Cytomedix's ability to execute on its strategy to market the AutoloGel™ System as contemplated, the Company's ability to successfully integrate the Angel® and activAT® product lines into its existing business, to assume and satisfy certain liabilities related to the Angel® and activAT® product lines. To the extent that any statements made here are not historical, these statements are essentially forward-looking. The Company uses words and phrases such as "believes", "forecasted," "projects," "is expected," "remain confident," "will" and/or similar expressions to identify forward-looking statements in this press release. Undue reliance should not be placed on forward-looking information. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from the forward-looking statements. More information about some of these risks and uncertainties may be found in the reports filed with the Securities and Exchange Commission by Cytomedix, Inc. Cytomedix operates in a highly competitive and rapidly changing business and regulatory environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. Except as is expressly required by the federal securities laws, Cytomedix undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason. Additional risks that could affect our future operating results are more fully described in our U.S. Securities and Exchange Commission filings, including our Annual Report for the year ended December 31, 2010, filed with the SEC and other subsequent filings. These filings are available at http://www.sec.gov.